Moleculin Biotech
MBRX
6 hedge funds and large institutions have $1.85M invested in Moleculin Biotech in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
1,631% more capital inflows, than outflows
Capital inflows: $433K | Capital outflows: $25K
50% more funds holding
Funds holding: 4 → 6 (+2)
0.37% more ownership
Funds ownership: 3.62% → 3.99% (+0.37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$173K |
| 2 |
Whitegate Investment Counselors
Concord,
New Hampshire
|
+$173K |
| 3 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$86.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Securities
New York
|
-$21K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4K |
MBRX Hedge Fund Activity: Q1 2018 in Review
6 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2018, worth a combined $1.85M — up 30% from $1.42M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new MBRX positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $173K. The largest seller was Two Sigma Securities, cutting an estimated $21K.
- 6 institutional investors held Moleculin Biotech (MBRX) as of Q1 2018, up from 4 in Q4 2017.
- Funds reported $1.85M of Moleculin Biotech stock for Q1 2018, up 30% quarter-over-quarter.
- 2 funds opened new Moleculin Biotech positions in Q1 2018 and 0 closed out, a net change of +2 holders.
- The largest Moleculin Biotech buyer in Q1 2018 was Vanguard Group, an estimated $173K added.
- The largest Moleculin Biotech seller in Q1 2018 was Two Sigma Securities, an estimated $21K sold.
Based on aggregated 13F filings for Q1 2018.